Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim

This article was originally published in Scrip

Executive Summary

Merck & Co. failed to convince the FDA to permit the firm to market its cholesterol-lowering medications Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as therapies to reduce the risk of cardiovascular (CV) events – CV death, nonfatal heart attacks and strokes, hospitalization for unstable angina or the need for revascularization – in patients with coronary heart disease.

Advertisement

Related Content

Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

SC064512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel